Published online Nov 7, 2014. doi: 10.3748/wjg.v20.i41.15413
Revised: May 17, 2014
Accepted: June 12, 2014
Published online: November 7, 2014
Processing time: 231 Days and 2.7 Hours
AIM: To conduct an updated meta-analysis of prospective studies addressing the association between garlic consumption and colorectal cancer.
METHODS: Eligible cohort studies were identified by searching MEDLINE (PubMed) and screening the references of related articles published up to October 2013. Meta-analyses were conducted for colorectal cancer in relation to consumption of raw and cooked (RC) garlic and garlic supplements, separately. The summary relative risks (RR) with 95%CI were calculated using fixed-effects or random-effects model depending on the heterogeneity among studies.
RESULTS: A total of 5 prospective cohort studies were identified. In contrast to the previous meta-analysis, no significant associations were found between consumption of RC garlic (RR: 1.06; 95%CI: 0.95-1.19) or garlic supplements (RR: 1.12; 95%CI: 0.96-1.31) and risk of colorectal cancer. A non-significant protective effect of garlic supplement intake against colorectal cancer was observed in females (RR: 0.84; 95%CI: 0.64-1.11), but the opposite was the case in males (RR: 1.24; 95%CI: 0.96-1.59).
CONCLUSION: Consumption of RC garlic or garlic supplements is not significantly associated with reduced colorectal cancer risk.
Core tip: Garlic is consumed worldwide as a food additive and botanical supplement. The previous meta-analysis, mostly based on case-control studies, suggested that garlic consumption was associated with reduced colorectal cancer risk; however, our updated meta-analysis based on high-quality prospective studies showed no significant association between garlic consumption and risk of colorectal cancer. The recommendation of garlic consumption as a nutrition intervention against colorectal cancer should be cautious.